Elizabeth Anderson, PhD

Scientific Director Oncology, Early Discovery
Elizabeth Anderson

Elizabeth is a Scientific Director in Early Discovery and has more than 30 years’ experience of oncology research and oncology drug discovery.  Before joining Charles River in February 2019, Dr Anderson spent 7 years as Scientific Director in External Research at Boehringer-Ingelheim where she was responsible for generating strategy and competitive intelligence to support Oncology research and development. Whilst at Boehringer-Ingelheim, she supported the entire Oncology portfolio from small molecule inhibitors to antibodies against immune—oncology targets and across the entire value chain from target selection up to the end of Phase II clinical development.  Before moving to Boehringer-Ingelheim, Dr Anderson worked at AstraZeneca UK as a Translational Science Strategist in Oncology where she was responsible for the later stage pre-clinical biology programmes for a number of different drugs across a range of tumour types. Prior to joining AstraZeneca, she led an academic translational research group at The Christie Hospital in Manchester, UK.